Abstract
Intranasal administration has gained an increasing interest for brain drug delivery since it allows direct transport through neuronal pathways, which can be quite advantageous for central nervous system disorders, such as depression and anxiety. Nanoparticles have been studied as possible alternatives to conventional formulations, with the objective of improving drug bioavailability. The present work aimed to analyze the potential of intranasal nanoparticle administration for the treatment of depression and anxiety, using the analysis of several studies already performed. From the carried-out analysis, it was concluded that the use of nanoparticles allows the drug’s protection from enzymatic degradation, and the modulation of its components allows controlled drug release and enhanced drug permeation. Furthermore, the results of in vivo studies further verified these systems’ potential, with the drug reaching the brain faster and leading to increased bioavailability and, consequently, therapeutic effect. Hence, in general, the intranasal administration of nanoparticles leads to a faster onset of action, with increased and prolonged brain drug concentrations and, consequently, therapeutic effects, presenting high potential as an alternative to the currently available therapies for the treatment of depression and anxiety.
Reference82 articles.
1. (2022, October 31). World Health Organization Mental Health. Available online: https://www.who.int/health-topics/mental-health#tab=tab_1.
2. Astrocytes and Major Depression: The Purinergic Avenue;Zhao;Neuropharmacology,2022
3. Gabriel, F.C., de Melo, D.O., Fráguas, R., Leite-Santos, N.C., Mantovani da Silva, R.A., and Ribeiro, E. (2020). Pharmacological Treatment of Depression: A Systematic Review Comparing Clinical Practice Guideline Recommendations. PLoS ONE, 15.
4. The State of Our Understanding of the Pathophysiology and Optimal Treatment of Depression: Glass Half Full or Half Empty?;Nemeroff;Am. J. Psychiatry,2020
5. Histamine and Histamine Receptors: Roles in Major Depressive Disorder;Qian;Front. Psychiatry,2022
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献